Posts belonging to Category Clinical Trials

Cytokinetics to Announce Results from BENEFIT-ALS at 66th Annual Meeting of the American Academy of Neurology

Cytokinetics, Incorporated announced today that results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) will be presented during a Platform Session scheduled at the 66th Annual Meeting of the American Academy of Neurology (AAN) to be held April 26 – May 3, 2014 at the Pennsylvania Convention Center in Philadelphia, PA.

Research and Markets: Global Amyotrophic Lateral Sclerosis Market Forecast 2014-2018

The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services.

Mayo Clinic Researchers Place ALS Hope in Stem Cells

The trial is a safety study to determine if it’s safe to give ALS patients injections of stem cells grown from samples of their own fat tissue.

Final Results of ALS Phase I Stem Cell Trial Published in Annals of Neurology

The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy in ALS patients.

Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats

The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients

BrainStorm and Mass General Sign Definitive Agreement for ALS Clinical Trial

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS).

ImStar Selects Lead ALS Drug Candidate for Study by Mid-2014

“We are very excited to announce the selection of IMS-088 as ImStar’s lead ALS compound. As we continue with preclinical development next year, we hope to establish IMS-088 as a safe and effective new drug candidate for ALS,” said Jean-Pierre Julien, ImStar’s chief scientific officer.

Neuraltus’ NP001 Phase 2 Results Highlighted at 24th International Symposium on ALS/MND

According to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and matched historical (placebo) controls. The high dose of NP001 (2mg/kg) halted progression in 27% of patients compared to 11% of patients on placebo. Further, NP001 was found to be safe and well-tolerated in the study.

Cytokinetics to Present BENEFIT-ALS Trial Insights at International Symposium

Cytokinetics will elaborate on the clinical trial design and include enrollment and baseline demographics data from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS), which is evaluating tirasemtiv, a novel mechanism skeletal muscle activator, as a potential treatment for patients with amyotrophic lateral sclerosis (ALS).

Acceleration of Clinical Program in ALS Confirms Proof of Efficacy Data Obtained in Animals

AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.